OR WAIT 15 SECS
© 2020 MJH Life Sciences and Drug Topics. All rights reserved.
© 2020 MJH Life Sciences™ and Drug Topics. All rights reserved.
September 18, 2020
Data showed that empagliflozin with standard of care was superior to placebo in reducing the risk of CV death or hospitalization.
A study compared cardiac events associated with azithromycin versus amoxicillin.
September 10, 2020
The study investigators used artificial intelligence to analyze gut microbiome data in individuals with and without cardiovascular disease.
September 08, 2020
Approval was based on a phase 3 clinical trial comparing the investigative doses with the approved 1.5 mg dose.
September 03, 2020
There is no evidence that blood pressure lowering drugs increase the risk of cancer, according to a major new study.
August 31, 2020
Dapagliflozin (Farxiga; AstraZeneca) demonstrated positive results in the phase 3 DAPA-CKD trial.
July 31, 2020
Empagliflozin (Jardiance; Eli Lilly) met the primary end point of a study for adults with heart failure with reduced ejection fraction with or without diabetes.
July 13, 2020
Azithromycin may be linked to a greater risk of cardiovascular death, according to a recent study.
July 03, 2020
A new study found increased plaque buildup levels in women with HIV who also suffered from persistent depression and stress.
July 02, 2020
Individuals recently diagnosed with type 2 diabetes were more likely to die from heart failure than any other cardiovascular disease, a study found.
June 01, 2020
This is the first regulatory approval for aspirin plus ticagrelor dual antiplatelet therapy for individuals with high cardiovascular risk but without prior instances of heart attack or stroke.
May 25, 2020
Women and older adults are underrepresented in clinical trials evaluating cholesterol medications, according to a new study published in JAMA Network Open.
May 20, 2020
Monitoring and controlling heart disease may be crucial in supporting cognitive health later in life.
May 15, 2020
A new study found that the use of PCSK9 inhibitors with maximally tolerated statins does not negatively affect the mental cognition of patients.
May 06, 2020
Results of the study showed that antihypertensive medications do not put individuals at increased risk for COVID-19.
Officials with the FDA have approved dapagliflozin (Farxiga, AstraZeneca) to reduce the risk of cardiovascular death and hospitalization in adults with heart failure with reduced ejection fraction, with and without type 2 diabetes.
April 23, 2020
Two new studies underscore health disparities in rural United States affecting mortality rates associated with cardiovascular disease.
April 01, 2020
Bempedoic acid (Nexletol, Esperion), an oral, once-daily, non-statin low-density lipoprotein-cholesterol lowering medicine, is now available in US pharmacies.
March 31, 2020
Ticagrelor alone, without aspirin, reduced bleeding without increasing the cardiovascular risks.
Alirocumab significantly reduced low-density lipoprotein cholesterol in adults with homozygous familial hypercholesterolemia, according to phase 3 data.